Elenestinib clinical trials
Also written BLU-263.
How each study uses elenestinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elenestinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses elenestinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisRecruitingPhase 2/3Blueprint Medicines CorporationNCT04910685Written as Elenestinib
- A Study of Elenestinib in Healthy Adult Female ParticipantsCompletedPhase 1Blueprint Medicines CorporationNCT07388511Written as Elenestinib
- Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedPhase 1Blueprint Medicines CorporationNCT05609942Written as BLU-263
Codes
What other systems call elenestinib · ClinicalTrials.gg INT015261
- UNII (FDA) 6FBM4CP6RKELENESTINIBConfirmed FDA, Wikidata
- Wikidata Q140645714elenestinibConfirmed FDA, Wikidata
- NCI Thesaurus C180833ElenestinibOne source FDA
- DrugBank DB18489One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6FBM4CP6RK | ELENESTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140645714 | elenestinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C180833 | Elenestinib | One source FDA |
| DrugBank | DB18489 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.